临床肝胆病杂志2018，Vol.34Issue(2)：251-254,4.DOI:10.3969/j.issn.1001-5256.2018.02.007
慢性丙型肝炎合并肾功能不全患者直接抗病毒药物治疗的选择
Selection of direct-acting antiviral agents in treatment of chronic hepatitis C patients with renal dysfunction
摘要
Abstract
The incidence of hepatitis C virus infection is commonly seen in patients with renal dysfunction (RD),especially those with end-stage renal disease on hemodialysis (HD),among whom the incidence and mortality of liver diseases increase.The development of direct-acting antiviral agents has revolutionized the therapy for chronic hepatitis C (CHC) with a sustained virologic response rate of ＞ 90％ and a low rate of adverse events.Grazoprevir/elbasvir,paritaprevir/ritonavir + ombitasvir + dasabuvir,glecaprevir/pibrentasvir,or daclatasvir + asunaprevir regimen is recommended in CHC patients with RD and HD,while the sofosbuvir-based regimen is not recommended.关键词
肝炎,丙型,慢性/肾功能不全/血液透析滤过/抗病毒药Key words
hepatitis C chronic/renal insufficiency/hemodiafiltration/antiviral agents分类
医药卫生引用本文复制引用
陈建宏,徐小元..慢性丙型肝炎合并肾功能不全患者直接抗病毒药物治疗的选择[J].临床肝胆病杂志,2018,34(2):251-254,4.基金项目
十二五重大专项(2012ZX10002003-004-003) （2012ZX10002003-004-003）
国家自然科学基金(81373056) （81373056）
